Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
DGX

DGX - Quest Diagnostics Inc Stock Price, Fair Value and News

125.34USD-1.39 (-1.10%)Market Closed
Watchlist

Market Summary

USD125.34-1.39
Market Closed
-1.10%

DGX Alerts

  • Big jump in Earnings (Y/Y)

DGX Stock Price

View Fullscreen

DGX RSI Chart

DGX Valuation

Market Cap

14.0B

Price/Earnings (Trailing)

16.44

Price/Sales (Trailing)

1.52

EV/EBITDA

12.47

Price/Free Cashflow

16.25

DGX Price/Sales (Trailing)

DGX Profitability

Operating Margin

33.00%

EBT Margin

12.21%

Return on Equity

13.47%

Return on Assets

6.09%

Free Cashflow Yield

6.15%

DGX Fundamentals

DGX Revenue

Revenue (TTM)

9.3B

Rev. Growth (Yr)

-1.93%

Rev. Growth (Qtr)

-0.31%

DGX Earnings

Earnings (TTM)

854.0M

Earnings Growth (Yr)

90.1%

Earnings Growth (Qtr)

-14.67%

Breaking Down DGX Revenue

Last 7 days

-2.2%

Last 30 days

-8.3%

Last 90 days

-8.1%

Trailing 12 Months

-14.4%

How does DGX drawdown profile look like?

DGX Financial Health

Current Ratio

1.31

Debt/Equity

0.7

Debt/Cashflow

0.29

DGX Investor Care

Dividend Yield

1.56%

Dividend/Share (TTM)

1.95

Buy Backs (1Y)

4.27%

Diluted EPS (TTM)

7.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20239.6B9.5B9.3B9.3B
202210.7B10.6B10.3B9.9B
202110.3B11.1B11.0B10.8B
20207.7B7.5B8.4B9.4B
20197.5B7.6B7.6B7.7B
20187.5B7.5B7.6B7.5B
20177.5B7.4B7.4B7.4B
20167.5B7.5B7.5B7.5B
20157.5B7.6B7.5B7.5B
20147.2B7.3B7.4B7.4B
20137.3B7.2B7.2B7.1B
20127.5B7.5B7.5B7.4B
20117.4B7.4B7.4B7.4B
20107.5B7.4B7.4B7.4B
20097.3B7.3B7.4B7.5B
20086.8B7.0B7.1B7.2B
20070006.7B

Tracking the Latest Insider Buys and Sells of Quest Diagnostics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 14, 2024
kuppusamy karthik
acquired
-
-
2,641
svp, clinical solutions
Feb 14, 2024
doherty catherine t.
acquired
-
-
4,304
svp, regional businesses
Feb 14, 2024
samad sam
acquired
-
-
5,478
executive vice president & cfo
Feb 14, 2024
davis j. e.
acquired
-
-
22,251
ceo and president
Feb 14, 2024
prevoznik michael e
acquired
-
-
2,935
svp & general counsel
Feb 14, 2024
deppe michael j
acquired
-
-
558
svp, corp. controller & cao
Feb 14, 2024
gardner mark a
acquired
-
-
2,250
svp of molecular gen & oncol
Feb 14, 2024
plewman patrick
acquired
-
-
2,446
svp for diagnostic services
Feb 14, 2024
delaney mark e
acquired
-
-
2,348
svp & chief commercial officer
Jan 31, 2024
plewman patrick
acquired
6,466
129
50.00
svp for diagnostic services

1–10 of 50

Which funds bought or sold DGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
Raleigh Capital Management Inc.
reduced
-97.06
-4,026
138
-%
Feb 21, 2024
V-Square Quantitative Management LLC
added
23.8
104,852
366,485
0.06%
Feb 20, 2024
Aurora Investment Counsel
added
2.16
206,789
1,976,320
1.28%
Feb 20, 2024
Wellington Wealth Strategies, LLC.
new
-
338,771
338,771
0.29%
Feb 20, 2024
Quarry LP
added
29.48
9,804
30,886
-%
Feb 16, 2024
D L CARLSON INVESTMENT GROUP INC
reduced
-14.05
-125,576
983,837
0.20%
Feb 16, 2024
WESBANCO BANK INC
reduced
-34.53
-117,832
336,705
0.02%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
added
1.98
4,773,650
35,788,000
0.04%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
17.96
90,030,000
359,063,000
0.05%
Feb 16, 2024
Aspect Partners, LLC
new
-
1,655
1,655
-%

1–10 of 42

Are Funds Buying or Selling DGX?

Are funds buying DGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DGX
No. of Funds

Unveiling Quest Diagnostics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.07%
13,575,974
SC 13G/A
Jan 25, 2024
state street corp
4.76%
5,352,341
SC 13G/A
Jan 24, 2024
blackrock inc.
9.4%
10,578,025
SC 13G/A
Feb 09, 2023
vanguard group inc
12.27%
13,973,339
SC 13G/A
Feb 07, 2023
state street corp
5.16%
5,879,980
SC 13G/A
Jan 23, 2023
blackrock inc.
10.9%
12,391,327
SC 13G/A
Apr 08, 2022
blackrock inc.
10.7%
12,807,624
SC 13G/A
Feb 10, 2022
state street corp
5.11%
6,268,789
SC 13G
Feb 07, 2022
blackrock inc.
9.5%
11,636,382
SC 13G/A
Feb 10, 2021
vanguard group inc
10.64%
14,337,685
SC 13G/A

Recent SEC filings of Quest Diagnostics Inc

View All Filings
Date Filed Form Type Document
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
144
Notice of Insider Sale Intent
Feb 22, 2024
144
Notice of Insider Sale Intent
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading

What is the Fair Value of DGX?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Quest Diagnostics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.9B
27.6B
10.99% -3.42%
39.24
6.77
-8.71% -33.92%
47.5B
3.7B
3.78% 14.37%
56.17
12.97
8.72% 24.44%
38.7B
6.8B
3.29% -11.61%
31.19
5.66
-0.22% -1.12%
14.0B
9.3B
-8.35% -14.36%
16.44
1.52
-6.38% -9.73%
12.7B
4.1B
15.83% -0.20%
26.72
3.07
3.86% -2.39%
11.1B
2.5B
-9.16% -4.81%
-54.17
4.42
19.93% 67.26%
MID-CAP
12.1B
1.9B
36.59% 75.21%
42.82
6.42
29.17% 15.26%
8.5B
988.7M
14.98% 63.69%
-17.12
8.65
27.41% 8.51%
3.7B
918.7M
-2.97% -10.18%
316.38
4.06
45.66% 172.57%
2.7B
563.9M
-7.36% -19.90%
-5.69
4.84
25.45% 26.76%
SMALL-CAP
447.4M
297.1M
-26.16% -46.86%
-4.94
1.51
-6.74% -21.60%
85.7M
21.4M
29.35% -91.67%
-0.75
4
-8.80% -39.66%
45.6M
9.2M
-1.43% -37.11%
-2.51
4.97
16.43% 46.89%
9.1M
13.4M
6.67% -61.68%
-0.91
0.68
-26.43% -20.54%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

Quest Diagnostics Inc News

Latest updates
MarketWatch13 hours ago
Yahoo Finance15 Feb 202412:58 pm
Zacks Investment Research06 Feb 202411:30 am
Yahoo Finance03 Jan 202408:00 am

Quest Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-0.3%2,2882,2952,3382,3312,3332,4862,4532,6112,7442,7742,5502,7203,0022,7861,8271,8221,9261,9561,9531,8911,839
Cost Of Revenue0.7%1,5521,5411,5461,5601,5751,6181,6111,6461,7181,6701,5651,6261,7331,5801,2211,2701,2641,2641,2651,2441,235
Costs and Expenses3.5%2,0211,9531,9902,0262,1982,0942,0652,0982,2082,1222,0172,0602,2072,0681,5441,6471,5631,6431,6461,6431,619
  S&GA Expenses7.1%407380416439563464422425464427429407447396360347349362362384356
EBITDA Margin9.8%0.15*0.14*0.14*0.14*0.16*0.19*0.21*0.25*0.26*0.28*0.29*0.25*0.22*0.20*0.15*0.15*0.16*0.14*0.14*--
Interest Expenses100.0%--40.00-37.00-35.00-32.00-33.00-36.00-37.00-37.00-38.00-38.00-38.00-39.00-42.00-41.00-41.00-42.00-44.00-45.00-44.00-43.00
Income Taxes-41.2%40.0068.0075.0065.00-4.0081.0077.0011011415317715319117766.0026.0072.0062.0063.0050.0040.00
Earnings Before Taxes-20.7%237299317277109351323452502654817626758753255118328270265213167
EBT Margin13.3%0.12*0.11*0.11*0.11*0.12*0.16*0.18*0.23*0.24*0.26*0.27*0.23*0.20*0.17*0.13*0.13*0.14*0.12*0.12*--
Net Income-14.7%19222523520210125623435539050563146957956818599.00253215226164127
Net Income Margin12.5%0.09*0.08*0.08*0.08*0.10*0.12*0.14*0.18*0.18*0.20*0.20*0.17*0.15*0.13*0.10*0.10*0.11*0.10*0.10*--
Free Cashflow346.1%455102340-33.00187384326417337472376645379771273164176203236--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets4.0%14,02213,48213,42512,79412,83713,22313,31213,44213,61113,57212,86113,93114,02614,14312,99012,04912,84312,01911,76011,93711,003
  Current Assets30.7%2,3721,8151,7331,8141,8982,3342,4262,4752,7412,8542,1462,9993,0583,3482,3801,5602,4901,7791,5661,7781,390
    Cash Equivalents379.7%6861431261753157007907128729875601,2301,1581,6059883421,192434273464135
  Inventory3.3%19018418419019218318719720820519922322320515412612311210598.0099.00
  Net PPE-0.8%1,8161,8301,8141,7951,7661,7071,6641,6681,7071,6341,6221,6241,6271,5441,5051,4611,4531,3511,3071,2771,288
  Goodwill0.0%7,7337,7322697,2417,2207,1907,1957,1977,0957,0577,0456,8706,8736,8806,78993.006,6196,617---
  Current Liabilities12.2%1,8151,6181,8751,3551,5511,6021,5771,7001,7531,7591,5511,7071,7762,3891,8431,1291,9902,0111,9042,2821,485
  Long Term Debt11.8%4,4103,9463,7773,9753,9783,9803,9833,9854,0104,0064,0084,0104,0134,0184,0204,0333,9663,1883,1693,1313,429
    LT Debt, Current-0.3%3033045182.002.002.002.002.002.001.002.002.002.005555553.00804---464
Shareholder's Equity-1.3%6,3426,4256,2876,0885,8936,2726,4506,4156,4836,4325,9406,7906,8096,4465,8815,7035,6875,6545,5095,3415,267
  Retained Earnings1.3%8,8258,7118,5668,4128,2908,2638,0837,9267,6497,33310,2469,6909,3038,8008,3078,1978,1747,9927,8497,6947,602
  Additional Paid-In Capital0.8%2,3202,3022,2842,2662,2952,2722,2502,2262,2601,9362,5552,8242,8412,8012,7642,7382,7222,7052,6862,6712,667
Shares Outstanding-100.0%-112112112-117118119-127125133-134134134-135135134-
Minority Interest-7.9%35.0038.0038.0038.0037.0037.0039.0038.0039.0040.0041.0045.0050.0046.0050.0046.0046.0049.0050.0051.0051.00
Float-------15,400---16,100---15,200---13,700--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations154.6%52720744494.00334502402480481561460731541862355247348299321275295
  Share Based Compensation5.6%19.0018.0016.0024.0022.0018.0019.0018.0019.0021.0021.0018.0034.0032.0017.0014.0012.0012.0015.0017.008.00
Cashflow From Investing-6.5%-114-107-682-158-174-118-82.00-169-227-96.00437-93.00-168-193-205-206-100-109-92.00-110-346
Cashflow From Financing256.6%130-83.00189-76.00-545-474-242-471-369-38.00-1,567-566-820-52.00496-891510-29.00-420164-77.00
  Dividend Payments0%80.0080.0080.0074.0075.0078.0078.0074.0077.0076.0081.0075.0075.0076.0075.0071.0071.0072.0071.0072.0068.00
  Buy Backs-275---461374200373289-1,500410250--75.0020050.0050.0053.00172

DGX Income Statement

2023-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net revenues$ 2,295$ 2,486$ 6,964$ 7,550
Operating costs and expenses and other operating income:    
Cost of services1,5411,6184,6474,875
Selling, general and administrative3804641,2351,311
Amortization of intangible assets27278181
Other operating expense (income), net5(15)6(10)
Total operating costs and expenses, net1,9532,0945,9696,257
Operating income3423929951,293
Other income (expense):    
Interest expense, net(40)(33)(112)(106)
Other (expense) income, net(3)(8)10(61)
Total non-operating expense, net(43)(41)(102)(167)
Income before income taxes and equity in earnings of equity method investees2993518931,126
Income tax expense(68)(81)(208)(268)
Equity in earnings of equity method investees, net of taxes661841
Net income237276703899
Less: Net income attributable to noncontrolling interests12204154
Net income attributable to Quest Diagnostics$ 225$ 256$ 662$ 845
Earnings per share attributable to Quest Diagnostics’ common stockholders:    
Basic (in dollars per share)$ 1.99$ 2.20$ 5.87$ 7.17
Diluted (in dollars per share)$ 1.96$ 2.17$ 5.79$ 7.05
Weighted average common shares outstanding:    
Basic (in Shares)112116112117
Diluted (in Shares)114118114119

DGX Balance Sheet

2023-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 143$ 315
Accounts receivable, net of allowance for credit losses of $27 and $30 as of September 30, 2023 and December 31, 2022, respectively1,2811,195
Inventories184192
Prepaid expenses and other current assets207196
Total current assets1,8151,898
Property, plant and equipment, net1,8301,766
Operating lease right-of-use assets607585
Goodwill7,7327,220
Intangible assets, net1,2191,092
Investments in equity method investees130132
Other assets149144
Total assets13,48212,837
Liabilities and Stockholders' Equity  
Accounts payable and accrued expenses1,1571,396
Current portion of long-term debt3042
Current portion of long-term operating lease liabilities157153
Total current liabilities1,6181,551
Long-term debt3,9463,978
Long-term operating lease liabilities505489
Other liabilities874812
Commitments and contingencies
Redeemable noncontrolling interest7677
Quest Diagnostics stockholders’ equity:  
Common stock, par value $0.01 per share; 600 shares authorized as of both September 30, 2023 and December 31, 2022; 162 shares issued as of both September 30, 2023 and December 31, 202222
Additional paid-in capital2,3022,295
Retained earnings8,7118,290
Accumulated other comprehensive loss(20)(21)
Treasury stock, at cost; 50 and 51 shares as of September 30, 2023 and December 31, 2022, respectively(4,570)(4,673)
Total Quest Diagnostics stockholders' equity6,4255,893
Noncontrolling interests3837
Total stockholders' equity6,4635,930
Total liabilities and stockholders' equity$ 13,482$ 12,837
DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
 CEO
 WEBSITEwww.questdiagnostics.com
 EMPLOYEES40000

Quest Diagnostics Inc Frequently Asked Questions


What is the ticker symbol for Quest Diagnostics Inc? What does DGX stand for in stocks?

DGX is the stock ticker symbol of Quest Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quest Diagnostics Inc (DGX)?

As of Thu Feb 22 2024, market cap of Quest Diagnostics Inc is 14.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers. The fair value of Quest Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quest Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quest Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether DGX is over valued or under valued. Whether Quest Diagnostics Inc is cheap or expensive depends on the assumptions which impact Quest Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DGX.

What is Quest Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, DGX's PE ratio (Price to Earnings) is 18.4 and Price to Sales (PS) ratio is 1.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Quest Diagnostics Inc's stock?

In the past 10 years, Quest Diagnostics Inc has provided 0.109 (multiply by 100 for percentage) rate of return.